en قلب Heart پژوهشي Research <p>Abstract<br> Background<br> Peripheral blood vessels, due to&nbsp;availability are used for many years in&nbsp;cancer patients, however in patients with&nbsp;potentially harmful drugs to skin (vesicant&nbsp;drugs) or difficult accessibility to vessels,&nbsp;the use of implantable port (totally&nbsp;implantable venous access port-TIVAP)devices with central vascular access are&nbsp;important.&nbsp;</p> <p>Materials and Methods<br> In this retrospective study, 85 pediatric&nbsp;cancer patients younger than 16 years,&nbsp;with TIVAP implantation, were followed<br> for their complications and outcome. In&nbsp;addition to demographic data, patients&rsquo;&nbsp;port complications were assessed and<br> compared with published articles.<br> Results<br> Mean days of implanted port usage were&nbsp;531 &plusmn; 358 days in all patients. This period&nbsp;was 287 &plusmn;194 days in complicated&nbsp;<br> patients. Complications included as&nbsp;infection (tunnel infection and catheter&nbsp;related blood-stream infection),&nbsp;malfunction and thrombosis, skin erosion,&nbsp;tube avulsion, and tube adhesion to the&nbsp;adjacent vessels were seen in 30.6% of&nbsp;patients.<br> Conclusion<br> According to the published data and this&nbsp;experience, the most common&nbsp;complications in TIVAP are infection and&nbsp;catheter malfunction. It is important to&nbsp;notice that in order to prolong its&nbsp;efficacious life, effective sterilization&nbsp;methods, prevention of clot formation and&nbsp;trauma, are the most useful measures.</p> Adverse effects, Complications, Malignancy, Pediatric, Vascular access device 1 8 http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-70-67&slc_lang=en&sid=1 H Esfahani Yes M Ghorbanpor No A Tanasan No